Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. SAVA

Cassava Sciences, Inc. is facing a securities fraud class action lawsuit filed by investors. The lawsuit alleges that the company made false and misleading statements regarding its drug candidate for Alzheimer’s disease.

Investors who purchased Cassava Sciences’ stock between February 2, 2021, and August 24, 2021, are included in the class action lawsuit. The lawsuit claims that the company overstated the results of its clinical trials and failed to disclose negative information about the drug candidate.

As a result of these alleged actions, Cassava Sciences’ stock price dropped significantly when the truth about the drug candidate’s efficacy was revealed. This led to financial losses for investors who purchased the stock during the specified time period.

It’s important for investors to stay informed about potential securities fraud lawsuits like this one. By doing thorough research and staying up to date on company news and developments, investors can protect themselves from potential financial losses.

If you are a Cassava Sciences investor who purchased stock during the specified time period, it is advisable to consult with a securities fraud attorney to learn more about your legal options in this class action lawsuit. Stay informed and protect your investments.